This website includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act. All statements included in this website that address activities, events or developments that Medicis expects, believes or anticipates will or may occur in the future are forward-looking statements. This includes earnings estimates, future financial performance, product development activities, potential or pending acquisitions of products or companies and other matters. These statements are based on certain assumptions made by Medicis based on its experience and perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Medicis. Any such projections or statements include the current views of Medicis with respect to such matters. No assurances can be given, however, that these events will occur, that such results will be achieved, that Medicis will continue to have the ability to pay any dividend, or that tax rates on cash dividends will not change. Medicis cannot validate its assumptions of the full impact on its business of the approval of competitive generic versions of its core brands, or any future competitive product approvals that may affect its brands. Also, there are a number of additional important factors that could cause actual results to differ materially from those projected, including the anticipated size of the markets for the companies' products; the availability of product supply; the receipt of required regulatory approvals for acquisitions; the ability to realize the anticipated synergies and benefits of acquisitions; access to available and feasible financing on a timely basis; the risks and uncertainties normally incident to the pharmaceutical and medical device industries including product liability claims; dependence on sales of key products; the uncertainty of future financial results and fluctuations in operating results; dependence on Medicis' strategy including the uncertainty of license payments and/or other payments due from third-parties; the timing and success of new product development by Medicis or third-parties; competitive product introductions; the risks of pending or future litigation or government investigations; and other risks described from time to time in Medicis' Securities and Exchange Commission ("SEC") filings including its Annual Reports on Form 10-K. There can be no assurance as to when or if any of the holders of the Notes will have the right to convert or if the Notes will be converted, and what impact the increase in the number of shares outstanding will have on its results of operations. Forward-looking statements represent the judgment of Medicis' management as of the date of this website's development and/or update, and Medicis disclaims any intent or obligation to update any forward-looking statements or to announce publicly any revision to any of the forward-looking statements contained in this website, or to make corrections to reflect future events or developments.